The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
A multiomic analysis led by the IrsiCaixa AIDS Research Institute has uncovered genetic and immune mechanisms in some ...
Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.